Amprenavir/Ritonavir, Saquinavir/Ritonavir or Efavirenz in HIV-Infected Subjects Following Failure With Kaletra (ABT-378/Ritonavir) as Their First Protease Inhibitor Based HAART
HIV Infections
About this trial
This is an interventional treatment trial for HIV Infections focused on measuring treatment experienced, HIV
Eligibility Criteria
Inclusion: Remain on present anti-HIV drugs during screening until a new regimen is started. Have a viral load of at least 1,000 copies/ml on the 2 most recent tests after at least 24 weeks of lopinavir/ritonavir and while still on it. Have an HIV which shows reduced susceptibility to lopinavir. Are at least 18 years old. Are not presently ill. Have not been treated for an opportunistic infection within 30 days of screening. Agree not to take certain drugs and agree to inform and get permission from the doctor before taking any medicines, over the counter medicines, herbal medicines, alcohol or recreational drugs. Agree to use an accepted barrier method of birth control. Exclusion: Female subject is pregnant or lactating. Have taken any protease inhibitor other than lopinavir/ritonavir for more that two weeks. Are taking chemotherapy. Have a medical problem with their pancreas. Have been screened for this study within the past 12 weeks. Appear to be unsuitable in the opinion of the doctor.
Sites / Locations
- Phoenix Body Positive, Inc.
- Paul J. Cimoch, M.D.
- AIDS Health Care Foundation - Research Center
- Tower Infectious Diseases Medical Associates
- 20th Avenue Medical Center Kaiser Permanente
- University of Colorado Health Sciences Center
- IDC Research Initiative
- Associates in Research
- Gary J. Richmond, M.D.
- University of Miami School of Medicine
- Infectious Disease Research Institute, Inc.
- AIDS Research Consortium of Atlanta, Inc.
- CORE Center
- Donna E. Sweet, M.D.
- David Parks, M.D.
- Saint Michael's Medical Center
- John B. Montana, M.D.
- Howard A. Grossman, M.D.
- State University of New York at Stony Brook
- University of Cincinnati Medical Center
- The Research & Education Group
- Bornemann Internal Medicine
- David Wright, M.D.
- University of Texas Medical Branch
- Diversified Medical Practices, P.A.
- Hampton Roads Medical Specialists
- Hospital Muniz - FUNDAI
- Fundacion Huesped
- Hospital Heliopolis
- Ottawa Hospital General Campus
- Toronto General Hospital Division of The University Health Network
- Montreal Chest Institute/Royal Victoria Hospital
- Hopital Michalon - C.H.U. de Grenoble
- Groupe Hospitalier Cochin -Saint-Vincent-de-Paul La Roche-Guyon
- Hopital Tenon
- Hospital Yves Le Foll
- La Seyne sur Mer, Hopital Chalucet
- C.H.U. Brabois - Tour Drouet, Rue du Morvan
- CORE Center
- Universitatsklinikum
- Klinikum J.W. Goethe Universitat
- Institut fur Immunologie Pathologie und Molekularbiologie
- Albrecht Ulmer, M.D.
- S. Raffaele Hospital
- Wojewodzki Szpital Zakazny
- Centro Familiar, Inc
- New Puerto Rico CONCRA
- Hospital Germans Trias I Pujol
- Hospital De La Sta Creu I San Pau
- Hospital Clinic I Provincial
- Hospital Carlos III
- Hospital La Paz
- Hospital Universitario Vergen del Rocio
- Royal Free Hospital